Cipla

NOW OFFERING

An FDA approved Therapeutic Equivalent to Somatuline® Depot*

Lanreotide Injection

120 mg/0.5 mL



NDC	69097-906-67
STRENGTH	120 mg/0.5 mL
RLD	Somatuline® Depot*
TE RATING	AB

SELLING UNIT	1
SELLING UNITS PER SHIPPER CASE	20
STORAGE	2°C to 8°C (36°F to 46°F). Protect from light.
SHELF LIFE	18 months

Please see following page for ordering instructions.

Indications

Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Important Safety Information

Contraindications: Hypersensitivity to lanreotide.

Warnings and Precautions

- **Cholelithiasis and Complications of Cholelithiasis:** Monitor patients periodically. Discontinue if complications of cholelithiasis are suspected. Gallstones may occur; consider periodic monitoring.
- **Hyperglycemia and Hypoglycemia:** Glucose monitoring is recommended and antidiabetic treatment adjusted accordingly.

Please see the following page for additional Important Safety Information and the accompanying full Prescribing Information as well as the Instructions for Use.

*Somatuline® Depot is a registered trademark of Ipsen Pharma S.A.S.

Medical Information:

- Report Adverse Events/Side Effects
- Report Product Complaints
- Submit Medical Inquiries:

Contact Us: 1-866-604-3268 DrugSafety@cipla.com

www.ciplalanreotide.com

Lanreotide Injection
120 mg/0.5 mL

To place your order, please contact your wholesaler

WHOLESALER/DISTRIBUTOR ORDER ENTRY NUMBER	
CENCORA	MCKESSON
10289332	2906519

To place your order directly with Cipla USA, please call 844-247-5287 or scan the QR code:

Most Common Adverse Reactions (>10%) include abdominal pain, musculoskeletal pain, vomiting, headache, injection site reaction, hyperglycemia, hypertension, and cholelithiasis.

Immunogenicity: There is potential for immunogenicity.

Drug Interactions

Insulin and Oral Hypoglycemic Drugs: Blood glucose levels should be monitored and antidiabetic treatment should be adjusted accordingly.

Cyclosporine: Lanreotide Injection may decrease the absorption of cyclosporine. Dosage adjustment of cyclosporine may be needed.

Bromocriptine: Lanreotide may increase the absorption of bromocriptine.

Bradycardia-Inducing Drugs (e.g., beta-blockers): Lanreotide Injection may decrease heart rate. Dosage adjustment of the coadministered drug may be necessary.

Drug Metabolism Interactions: Avoid other drugs mainly metabolized by CYP3A4 and which have a low therapeutic index (e.g., quinidine, terfenadine). Drugs metabolized by the liver may be metabolized more slowly during Lanreotide Injection treatment; dose reductions of the concomitantly administered medications should be considered.

Use in Specific Populations

Pregnancy: The risk of major birth defects and miscarriage is unknown.

Lactation: Advise women not to breastfeed during treatment with Lanreotide Injection and for 6 months following the last dose.

Females and Males of Reproductive Potential: Lanreotide Injection may reduce fertility in females of reproductive potential.

Geriatric Use: Dose selection for an elderly patient should be cautious.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Cipla at 1-866-604-3268.

Please see the accompanying full Prescribing Information for additional Important Safety Information.



Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059
Customer Service Tel.: 844-CIPLA US (844-247-5287)
Email: Cipla.CS@cipla.com

JUNE 2024 CUSAI-06042024-07